Identification Generic Name (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime DrugBank Accession Number DB08553 Background (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group. It targets the protein serine/threonine-protein kinase B-raf. 
 Type Small Molecule Groups Experimental Structure 
 
 
 3D Download  MOL SDF 3D-SDF PDB SMILES InChI 
 
 
  Similar Structures Structure for (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime (DB08553) ×  Close Weight Average: 373.4509  Monoisotopic: 373.190260383  Chemical Formula C 22 H 23 N 5 O Synonyms Not Available Pharmacology Indication Not Available Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. See how     Build, train, & validate predictive machine-learning models with structured datasets. See how Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events Improve clinical decision support with information on  contraindications & blackbox warnings, population restrictions, harmful risks, & more. Learn more     Avoid life-threatening adverse drug events & improve clinical decision support. Learn more Pharmacodynamics Not Available Mechanism of action Target Actions Organism U Serine/threonine-protein kinase B-raf Not Available Humans Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half-life Not Available Clearance Not Available Adverse Effects Improve decision support & research outcomes With structured adverse effects data, including:  blackbox warnings, adverse reactions, warning & precautions, & incidence rates. Learn more     Improve decision support & research outcomes with our structured adverse effects data. Learn more Toxicity Not Available Pathways Not Available Pharmacogenomic Effects/ADRs  
 
 
 Not Available Interactions Drug Interactions  
 
 
 This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.  Not Available Food Interactions Not Available Categories Drug Categories Not Available Chemical Taxonomy Provided by  Classyfire Description This compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring. Kingdom Organic compounds Super Class Benzenoids Class Indanes Sub Class Not Available Direct Parent Indanes Alternative Parents Pyridines and derivatives  /  Piperidines  /  Pyrazoles  /  Ketoximes  /  Heteroaromatic compounds  /  Dialkylamines  /  Azacyclic compounds  /  Organopnictogen compounds  /  Organic oxygen compounds  /  Hydrocarbon derivatives Substituents Amine  /  Aromatic heteropolycyclic compound  /  Azacycle  /  Azole  /  Heteroaromatic compound  /  Hydrocarbon derivative  /  Indane  /  Ketoxime  /  Organic nitrogen compound  /  Organic oxygen compound Molecular Framework Aromatic heteropolycyclic compounds External Descriptors Not Available Affected organisms Not Available Chemical Identifiers UNII Not Available CAS number Not Available InChI Key KWEFZSZCLBHIEQ-YYADALCUSA-N InChI InChI=1S/C22H23N5O/c28-26-21-4-2-16-13-17(1-3-19(16)21)20-14-27(18-7-11-24-12-8-18)25-22(20)15-5-9-23-10-6-15/h1,3,5-6,9-10,13-14,18,24,28H,2,4,7-8,11-12H2/b26-21+ IUPAC Name N-[(1E)-5-[1-(piperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2,3-dihydro-1H-inden-1-ylidene]hydroxylamine SMILES O\N=C1/CCC2=CC(=CC=C12)C1=CN(N=C1C1=CC=NC=C1)C1CCNCC1 References General References Not Available External Links PubChem Compound 11653652 PubChem Substance 99445024 ChemSpider 9828390 BindingDB 50006650 ChEMBL CHEMBL526479 ZINC ZINC000039110119 PDBe Ligand SM5 PDB Entries 3d4q  /  3omv Clinical Trials Clinical Trials  
 
 
 Phase Status Purpose Conditions Count Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage Forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Property Value Source Water Solubility 0.0387 mg/mL ALOGPS logP 2.39 ALOGPS logP 1.14 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 7.42 Chemaxon pKa (Strongest Basic) 10.12 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 75.33 Å 2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 120.35 m 3 ·mol -1 Chemaxon Polarizability 41.93 Å 3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon Predicted ADMET Features Property Value Probability Human Intestinal Absorption + 0.993 Blood Brain Barrier + 0.9283 Caco-2 permeable - 0.5819 P-glycoprotein substrate Substrate 0.6194 P-glycoprotein inhibitor I Non-inhibitor 0.6358 P-glycoprotein inhibitor II Inhibitor 0.6311 Renal organic cation transporter Inhibitor 0.622 CYP450 2C9 substrate Non-substrate 0.7101 CYP450 2D6 substrate Non-substrate 0.7173 CYP450 3A4 substrate Non-substrate 0.5384 CYP450 1A2 substrate Inhibitor 0.67 CYP450 2C9 inhibitor Non-inhibitor 0.6444 CYP450 2D6 inhibitor Non-inhibitor 0.755 CYP450 2C19 inhibitor Non-inhibitor 0.6576 CYP450 3A4 inhibitor Non-inhibitor 0.6395 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6793 Ames test AMES toxic 0.5606 Carcinogenicity Non-carcinogens 0.8004 Biodegradation Not ready biodegradable 0.9937 Rat acute toxicity 2.5303 LD50, mol/kg  Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6295 hERG inhibition (predictor II) Inhibitor 0.7564    ADMET data is predicted using  admetSAR , a free tool for evaluating chemical ADMET properties. ( 23092397 )  Spectra Mass Spec (NIST) Not Available Spectra Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available Targets Build, predict & validate machine-learning models Use our structured and evidence-based datasets to  unlock newinsights and accelerate drug research. Learn more     Use our structured and evidence-based datasets to unlock new insights and accelerate drug research. Learn more 
 
 
  Details 1.  Serine/threonine-protein kinase B-raf Kind Protein Organism Humans Pharmacological action Unknown General Function Protein serine/threonine kinase activity Specific Function Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, a... Gene Name BRAF Uniprot ID P15056 Uniprot Name Serine/threonine-protein kinase B-raf Molecular Weight 84436.135 Da References Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [ Article ]  × Identify potential medication risks Easily compare up to 40 drugs with our drug interaction checker. Get severity rating, description, and management advice.  Learn more      Drug created at September 15, 2010 21:32 / Updated at June 12, 2020 16:52 